A61K 47/6835
The modifying agent being an antibody or an immunoglobulin bearing at least
Official title: {the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}
A61K47/6835 (The modifying agent being an antibody or an immunoglobulin bearing at least) appears on 5,444 US grants and 10,056 published applications in this corpus.
Search patents in A61K- Granted patents
- 5,444
- Published applications
- 10,056
- Assignees
- 2,553
- Inventors
- 14,949
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 4 | 0 |
| 1984 | 4 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 5 | 0 |
| 1988 | 6 | 0 |
| 1989 | 10 | 0 |
| 1990 | 17 | 0 |
| 1991 | 24 | 0 |
| 1992 | 23 | 0 |
| 1993 | 33 | 0 |
| 1994 | 28 | 0 |
| 1995 | 24 | 0 |
| 1996 | 45 | 0 |
| 1997 | 61 | 0 |
| 1998 | 73 | 0 |
| 1999 | 66 | 0 |
| 2000 | 56 | 0 |
| 2001 | 46 | 17 |
| 2002 | 48 | 93 |
| 2003 | 48 | 121 |
| 2004 | 41 | 122 |
| 2005 | 25 | 156 |
| 2006 | 62 | 144 |
| 2007 | 49 | 130 |
| 2008 | 60 | 155 |
| 2009 | 83 | 195 |
| 2010 | 85 | 202 |
| 2011 | 95 | 246 |
| 2012 | 120 | 223 |
| 2013 | 142 | 252 |
| 2014 | 167 | 359 |
| 2015 | 206 | 412 |
| 2016 | 270 | 567 |
| 2017 | 330 | 561 |
| 2018 | 322 | 569 |
| 2019 | 355 | 597 |
| 2020 | 370 | 553 |
| 2021 | 369 | 676 |
| 2022 | 323 | 649 |
| 2023 | 346 | 716 |
| 2024 | 363 | 851 |
| 2025 | 383 | 818 |
| 2026 | 249 | 672 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 47/6849The antibody targeting a receptor, a cell surface antigen or a cell2,779
- A61K 47/6851The antibody targeting a determinant of a tumour cell2,611
- A61K 47/6843The antibody targeting a material from animals or humans418
- A61K 47/6845The antibody targeting a cytokine304
- A61K 47/6875The antibody being a hybrid immunoglobulin286
- A61K 47/6883Polymer-drug antibody conjugates256
- A61K 47/6871The antibody targeting an enzyme236
- A61K 47/6839The antibody targeting material from viruses134
All 12 subgroupsShow fewer
- A61K 47/6873The antibody targeting an immunoglobulin74
- A61K 47/6887Antibody-chelate conjugates using chelates for therapeutic purposes70
- A61K 47/6881Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies60
- A61K 47/6847The antibody targeting a hormone or a hormone-releasing or -inhibiting factor36
Recent patents
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Delivery of dual payload of mmaf or mmae and tlr7 agonists8 Oct 2026US 2026/0306648 A1The Research Foundation for The State University of New York
- Camptothecin drug conjugate and use thereof8 Oct 2026US 2026/0306650 A1Shanghai Zaimo Biotechnology Co., Ltd.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives8 Oct 2026US 2026/0306652 A1Merck Sharp & Dohme Corp.
- Fap-targeted antibody-drug conjugates8 Oct 2026US 2026/0306653 A1Oncomatryx Biopharma, S.L.
Most cited
By later US patents
- Polypeptide variants1,041US 6,194,551 B1Genentech, Inc. · 2001
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Chimeric antibody with specificity to human B cell surface antigen853US 5,500,362 AXoma Corporation · 1996
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma744US 5,736,137 AIDEC Pharmaceuticals Corporation · 1998
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011